News und Analysen
A Deeper Dive Into 2 Huge Rivian Victories
While 2025 could shape up into a rather quiet year for Rivian Automotive (NASDAQ: RIVN), with a lack of major launches or catalysts, the end of 2024 has been anything but muted. Investors have to
EQS-Adhoc: Airbus reports share buyback transactions 16-20 December 2024
Is Merck the Next Big Weight-Loss Stock?
Watch out, Eli Lilly and Novo Nordisk. Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs market.
Amidst an evolving field of competitors, the big pharma is committing
Is Lucid Taking a Page out of Rivian's Playbook?
The automotive industry can be a bit of a copycat industry. When one automaker finds success with a certain strategy, you can bet the competitors across the street take notice. We might be seeing
Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks
Collecting dividend income on a recurring basis can help strengthen your financial position and be a way for you to be less dependent on other sources of cash flow. The one downside is that many
QuantumScape: Buy, Sell, or Hold?
Electric vehicles (EVs) could be a game changer for transportation, but the technology still faces barriers to wider adoption. One common criticism is that they take too long to charge, and another
EQS-Adhoc: MTU Aero Engines AG: MTU Aero Engines AG appoints new CEO
EQS-Adhoc: Airbus reports share buyback transactions 9-13 December 2024
EQS-News: MVM Group to acquire the majority share of E.ON Energie Romania
EQS-Adhoc: Vonovia SE and Deutsche Wohnen SE agree on conclusion of domination and profit and loss transfer agreement and on the exchange ratio for the compensation and the fixed annual p
PUMA Opens New Creative Hub Studio48 to Foster Excellence in Design and Elevate the Brand
Sports company PUMA has opened Studio48, a new creative hub at its headquarters in Herzogenaurach, Germany, where its designers and creatives can come together to freely develop new ideas and
PUMA eröffnet Studio48, um herausragendes Design zu fördern und die Marke zu stärken
Das Sportunternehmen PUMA hat am Hauptsitz in Herzogenaurach das Studio48 eröffnet, in dem Designer*innen neue Ideen entwickeln und Konzepte für neue Performance- und Sportstyle-Produkte sowie
EQS-News: Zalando and ABOUT YOU Team Up to Lead the Way in European Fashion and Lifestyle E-commerce
EQS-Adhoc: Zalando SE: Agreement on business combination and public takeover offer to the shareholders of ABOUT YOU Holding SE.
Media Release: Allianz lifts financial ambitions at its Capital Markets Day 2024
Outperforming on key 2024 financial targets, Allianz has set ambitious financial targets through 2027 at its Capital Markets Day 2024.
This press release features multimedia. View the full
EQS-Adhoc: Allianz SE: Amendment to Dividend Policy
EQS-Adhoc: Airbus reports share buyback transactions 2-6 December 2024
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study met its primary
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved HYRNUO® (sevabertinib), an oral, reversible, tyrosine kinase inhibitor (TKI), for the treatment of adult patients
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
Today, on World Science Day, Bayer is proud to launch its “Science Delivers” campaign, a nationwide initiative celebrating how science delivers answers, hope, and progress for all Americans—every
Dr. Judith Hartmann to Become New Chief Financial Officer of Bayer AG
The Supervisory Board of Bayer AG has appointed Dr. Judith Hartmann to the company’s Board of Management, effective March 1, 2026. She will succeed Wolfgang Nickl as the company’s Chief Financial